SARS-CoV-2 Omicron变异株的研究进展
Research Progress of SARS-CoV-2 Omicron Variant
摘要: 拥有较强变异能力的严重急性呼吸综合征冠状病毒2 (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2)在新型冠状病毒肺炎疫情长期流行的过程中不断发生变异进化。2021年11月，一种刺突蛋白携带大量突变的SARS-CoV-2变异株在南非博茨瓦纳出现并被命名为“Omicron”，随后该毒株迅速取代Delta变异株成为现阶段全球流行毒株。与此前流行毒株相比，Omicron变异株具有更高的传染性和较强的免疫逃逸能力，其蔓延是当下全球2019冠状病毒病(Corona Virus Disease 2019, COVID-19)日新增确诊病例居高不下的关键因素。本文就Omicron变异株的起源、免疫逃逸机制及毒株致病性等方面进行综述。在总结Omicron变异株特点的同时分析该变异毒株对疫苗接种策略的潜在影响，以期为该变异毒株及将来可能出现的新发毒株的防控提供参考。
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with strong mutation ability has continuously mutated and evolved during the long-term epidemic of novel coronavirus pneumonia. In November 2021, a novel variant with a large number of mutations in spike protein appeared in Botswana of South Africa and was named “Omicron”, and then this lineage quickly replaced the Delta variants and became the current global epidemic lineage. Compared with previous epidemic variants, Omicron variant with higher infectivity and stronger immune evasion ability, the spread of this variant led to the current high number of daily confirmed cases of Corona Virus Disease 2019 (COVID-19) around the world. In this paper, the origin of Omicron variants, the immune escape mechanism and pathogenicity of this variant were reviewed. While summarizing the features of Omicron, the potential impact of Omicron variant on vaccination strategy is analyzed, so as to provide reference for the prevention of Omicron and possible emergence of new variants in the future.
文章引用：王康泓. SARS-CoV-2 Omicron变异株的研究进展[J]. 微生物前沿, 2022, 11(2): 49-60. https://doi.org/10.12677/AMB.2022.112006

参考文献

[1] World Health Organization (2022, February 21) WHO Coronavirus Disease (COVID-19) Dashboard.
https://covid19.who.int/
[2] Yurkovetskiy, L., Wang, X., Pascal, K.E., et al. (2020) Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. Cell, 183, 739-751.E8. [Google Scholar] [CrossRef] [PubMed]
[3] World Health Organization (n.d.) Tracking SARS-CoV-2 Variants.
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
[4] GISAID (2022) Tracking of Variants.
https://www.gisaid.org/hcov19-variants/
[5] PANGO (2022) PANGO Lineages: Latest Epidemiological Lineages of SARS-CoV-2.
https://cov-lineages.org/global_report_B.1.1.529.html
[6] Chen, J., Wang, R., Gilby, N.B., et al. (2022) Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. Journal of Chemical Information and Modeling, 62, 412-422. [Google Scholar] [CrossRef] [PubMed]
[7] 吴俣, 刘珏, 刘民, 等. 新型冠状病毒Omicron变异株的流行病学特征及防控研究[J]. 中国全科医学, 2022, 25(1): 14-19.
[8] Khandia, R., Singhal, S., Alqahtani, T., et al. (2022) Emergence of SARS-CoV-2 Omicron (B.1.1.529) Variant, Salient Features, High Global Health Concerns and Strategies to Counter It Amid Ongoing COVID-19 Pandemic. Environmental Research, 209, Article ID: 112816. [Google Scholar] [CrossRef] [PubMed]
[9] 王康泓. SARS-CoV-2感染机制分析与COVID-19治疗药物研究进展[J]. 生命科学研究, 2020, 24(6): 442-451.
[10] Gao, G.F. and Wang, L. (2021) COVID-19 Expands Its Territories from Humans to Animals. China CDC Weekly, 3, 855-858. [Google Scholar] [CrossRef] [PubMed]
[11] Mishra, A., Kumar, N., Bhatia, S., et al. (2021) SARS-CoV-2 Delta Variant among Asiatic Lions, India. Emerging Infectious Diseases, 27, 2723-2725. [Google Scholar] [CrossRef] [PubMed]
[12] Ferasin, L., Fritz, M., Ferasin, H., et al. (2021) Infection with SARS-CoV-2 variant, B.1.1.7 Detected in a Group of Dogs and Cats with Suspected Myocarditis. Veterinary Record, 189, e944. [Google Scholar] [CrossRef] [PubMed]
[13] Wei, C., Shan, K.J., Wang, W., et al. (2021) Evidence for a Mouse Origin of the SARS-CoV-2 Omicron Variant. Journal of Genetics and Genomics, 48, 1111-1121. [Google Scholar] [CrossRef] [PubMed]
[14] McCallum, M., Czudnochowski, N., Rosen, L.E., et al. (2022) Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement. Science, 375, 864-868. [Google Scholar] [CrossRef] [PubMed]
[15] 周玉霞, 王彩红, 姚晓文, 等. 免疫抑制人群与SARS-CoV-2变异相关性研究进展[J]. 海南医学院学报, 2022(5): 321-325.
[16] Jensen, B., Luebke, N., Feldt, T., et al. (2021) Emergence of the E484K Mutation in SARS-CoV-2-Infected Immunocompromised Patients Treated with Bamlanivimab in Germany. The Lancet Regional Health—Europe, 8, Article ID: Article ID: 100164. [Google Scholar] [CrossRef] [PubMed]
[17] Choi, B., Choudhary, M.C., Regan, J., et al. (2020) Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. New England Journal of Medicine, 383, 2291-2293. [Google Scholar] [CrossRef] 
[18] Avanzato, V.A., Matson, M.J., Seifert, S.N., et al. (2020) Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell, 183, 1901-1912.e9. [Google Scholar] [CrossRef] [PubMed]
[19] Truong, T.T., Ryutov, A., Pandey, U., et al. (2021) Increased Viral Variants in Children and Young Adults with Impaired Humoral Immunity and Persistent SARS-CoV-2 Infection: A Consecutive Case Series. EBioMedicine, 67, Article ID: 103355. [Google Scholar] [CrossRef] [PubMed]
[20] He, Y., Ma, W., Dang, S., et al. (2022) Possible Recombination between Two Variants of Concern in a COVID-19 Patient. Emerging Microbes & Infections, 11, 552-555. [Google Scholar] [CrossRef] [PubMed]
[21] Minskaia, E., Hertzig, T., Gorbalenya, A.E., et al. (2006) Discovery of an RNA Virus 3’→5’ Exoribonuclease That Is Critically Involved in Coronavirus RNA Synthesis. Proceedings of the National Academy of Sciences of the United States of America, 103, 5108-5113. [Google Scholar] [CrossRef] [PubMed]
[22] McCarthy, K.R., Rennick, L.J., Nambulli, S., et al. (2021) Recurrent Deletions in the SARS-CoV-2 Spike Glycoprotein Drive Antibody Escape. Science, 371, 1139-1142. [Google Scholar] [CrossRef] [PubMed]
[23] Papanikolaou, V., Chrysovergis, A., Ragos, V., et al. (2022) From Delta to Omicron: S1-RBD/S2 Mutation/Deletion Equilibrium in SARS-CoV-2 Defined Variants. Gene, 814, Article ID: 146134. [Google Scholar] [CrossRef] [PubMed]
[24] CoVariants (2022) Variant: 21K (Omicron).
https://covariants.org/variants/21K.Omicron
[25] Koley, T., Kumar, M., Goswami, A., et al. (2022) Structural Modeling of Omicron Spike Protein and Its Complex with Human ACE-2 Receptor: Molecular Basis for High Transmissibility of the Virus. Biochemical and Biophysical Research Communications, 592, 51-53. [Google Scholar] [CrossRef] [PubMed]
[26] Wu, L., Zhou, L., Mo, M., et al. (2022) SARS-CoV-2 Omicron RBD Shows Weaker Binding Affinity than the Currently Dominant Delta Variant to Human ACE2. Signal Transduction and Targeted Therapy, 7, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
[27] Lupala, C.S., Ye, Y., Chen, H., et al. (2022) Mutations on RBD of SARS-CoV-2 Omicron Variant Result in Stronger Binding to Human ACE2 Receptor. Biochemical and Biophysical Research Communications, 590, 34-41. [Google Scholar] [CrossRef] [PubMed]
[28] Khan, A., Waris, H., Rafique, M., et al. (2022) The Omicron (B.1.1.529) Variant of SARS-CoV-2 Binds to the hACE2 Receptor More Strongly and Escapes the Antibody Response: Insights from Structural and Simulation Data. International Journal of Biological Macromolecules, 200, 438-448. [Google Scholar] [CrossRef] [PubMed]
[29] Omotuyi, O., Olubiyi, O., Nash, O., et al. (2022) SARS-CoV-2 Omicron Spike Glycoprotein Receptor Binding Domain Exhibits Super-Binder Ability with ACE2 but Not Convalescent Monoclonal Antibody. Computers in Biology and Medicine, 142, Article ID: 105226. [Google Scholar] [CrossRef] [PubMed]
[30] Mannar, D., Saville, J.W., Zhu, X., et al. (2022) SARS-CoV-2 Omicron Variant: Antibody Evasion and Cryo-EM Structure of Spike Protein-ACE2 Complex. Science, 375, 760-764. [Google Scholar] [CrossRef] [PubMed]
[31] Fang, F.F. and Shi, P.Y. (2022) Omicron: A Drug Developer’s Perspective. Emerging Microbes & Infections, 11, 208-211. [Google Scholar] [CrossRef] [PubMed]
[32] Zahradník, J., Marciano, S., Shemesh, M., et al. (2021) SARS-CoV-2 Variant Prediction and Antiviral Drug Design Are Enabled by RBD In Vitro Evolution. Nature Microbiology, 6, 1188-1198. [Google Scholar] [CrossRef] [PubMed]
[33] Sharma, V., Rai, H., Gautam, D.N.S., et al. (2022) Emerging Evidence on Omicron (B.1.1.529) SARS-CoV-2 Variant. Journal of Medical Virology, 94, 1876-1885. [Google Scholar] [CrossRef] [PubMed]
[34] Singh, A., Steinkellner, G., Köchl, K., et al. (2021) Serine 477 Plays a Crucial Role in the Interaction of the SARS-CoV-2 Spike Protein with the Human Receptor ACE2. Scientific Reports, 11, Article No. 4320. [Google Scholar] [CrossRef] [PubMed]
[35] Han, P., Li, L., Liu, S., et al. (2022) Receptor Binding and Complex Structures of Human ACE2 to Spike RBD from Omicron and Delta SARS-CoV-2. Cell, 185, 630-640.e10. [Google Scholar] [CrossRef] [PubMed]
[36] Dejnirattisai, W., Huo, J., Zhou, D., et al. (2022) SARS-CoV-2 Omicron-B.1.1.529 Leads to Widespread Escape from Neutralizing Antibody Responses. Cell, 185, 467-484.e15. [Google Scholar] [CrossRef] [PubMed]
[37] Zhao, H., Lu, L., Peng, Z., et al. (2022) SARS-CoV-2 Omicron Variant Shows Less Efficient Replication and Fusion Activity When Compared with Delta Variant in TMPRSS2-Expressed Cells. Emerging Microbes & Infections, 11, 277-283. [Google Scholar] [CrossRef] [PubMed]
[38] Bojkova, D., Widera, M., Ciesek, S., et al. (2022) Reduced Interferon Antagonism but Similar Drug Sensitivity in Omicron Variant Compared to Delta Variant of SARS-CoV-2 Isolates. Cell Research, 32, 319-321. [Google Scholar] [CrossRef] [PubMed]
[39] Meng, B., Abdullahi, A., Ferreira, I.A.T.M., et al. (2022) Altered TMPRSS2 Usage by SARS-CoV-2 Omicron Impacts Tropism and Fusogenicity. Nature, 603, 709-714.
[40] Xia, X. (2020) Extreme Genomic CpG Deficiency in SARS-CoV-2 and Evasion of Host Antiviral Defense. Molecular Biology and Evolution, 37, 2699-2705. [Google Scholar] [CrossRef] [PubMed]
[41] Viswanathan, T., Arya, S., Chan, S.H., et al. (2020) Structural Basis of RNA cap Modification by SARS-CoV-2. Nature Communications, 11, Article No. 3718. [Google Scholar] [CrossRef] [PubMed]
[42] Yan, L., Yang, Y., Li, M., et al. (2021) Coupling of N7-Methyltransferase and 3’-5’Exoribonuclease with SARS-CoV-2 Polymerase Reveals Mechanisms for Capping and Proofreading. Cell, 184, 3474-3485.E11. [Google Scholar] [CrossRef] [PubMed]
[43] Mu, J., Xu, J., Zhang, L., et al. (2020) SARS-CoV-2-Encoded Nucleocapsid Protein Acts as a Viral Suppressor of RNA Interference in Cells. Science China Life Sciences, 63, 1413-1416. [Google Scholar] [CrossRef] [PubMed]
[44] Fu, Y.Z., Wang, S.Y., Zheng, Z.Q., et al. (2021) SARS-CoV-2 Membrane Glycoprotein M Antagonizes the MAVS-Mediated Innate Antiviral Response. Cellular & Molecular Immunology, 18, 613-620. [Google Scholar] [CrossRef] [PubMed]
[45] Xia, H., Cao, Z., Xie, X., et al. (2020) Evasion of Type I Interferon by SARS-CoV-2. Cell Reports, 33, Article ID: 108234. [Google Scholar] [CrossRef] [PubMed]
[46] Chen, K., Xiao, F., Hu, D., et al. (2020) SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-β Production. Viruses, 13, Article No. 47. [Google Scholar] [CrossRef] [PubMed]
[47] Li, J.Y., Liao, C.H., Wang, Q., et al. (2020) The ORF6, ORF8 and Nucleocapsid Proteins of SARS-CoV-2 Inhibit Type I Interferon Signaling Pathway. Virus Research, 286, Article ID: 198074. [Google Scholar] [CrossRef] [PubMed]
[48] Mu, J., Fang, Y., Yang, Q., et al. (2020) SARS-CoV-2 N Protein Antagonizes Type I Interferon Signaling by Suppressing Phosphorylation and Nuclear Translocation of STAT1 and STAT2. Cell Discovery, 6, Article No. 65. [Google Scholar] [CrossRef] [PubMed]
[49] Cao, Z., Xia, H., Rajsbaum, R., et al. (2021) Ubiquitination of SARS-CoV-2 ORF7a Promotes Antagonism of Interferon Response. Cellular & Molecular Immunology, 18, 746-748. [Google Scholar] [CrossRef] [PubMed]
[50] 马睿忆, 董晓婧, 肖霞, 等. SARS-CoV-2非结构蛋白1抑制Ⅰ型干扰素应答反应[J]. 国际病毒学杂志, 2021, 28(2): 116-119.
[51] Polycarpou, A., Howard, M., Farrar, C.A., et al. (2020) Rationale for Targeting Complement in COVID-19. EMBO Molecular Medicine, 12, Article No. e12642. [Google Scholar] [CrossRef] [PubMed]
[52] Noris, M., Benigni, A., Remuzzi, G. (2020) The Case of Complement Activation in COVID-19 Multiorgan Impact. Kidney International, 98, 314-322. [Google Scholar] [CrossRef] [PubMed]
[53] Tian, W., Zhang, N., Jin, R., et al. (2020) Immune Suppression in the Early Stage of COVID-19 Disease. Nature Communications, 11, Article No. 5859. [Google Scholar] [CrossRef] [PubMed]
[54] Schmidt, F., Muecksch, F., Weisblum, Y., et al. (2021) Plasma Neutralization Properties of the SARS-CoV-2 Omicron Variant. medRxiv. [Google Scholar] [CrossRef] [PubMed]
[55] YangYang, Gong, X., Yang, L., et al. (2022) Regular and Booster Vaccination with Inactivated Vaccines Enhance the Neutralizing Activity against Omicron Variant both in the Breakthrough Infections and Vaccines. Journal of Infection, 84, 579-613. [Google Scholar] [CrossRef] [PubMed]
[56] Lu, L., Mok, B.W., Chen, L.L., et al. (2021) Neutralization of SARS-CoV-2 Omicron Variant by Sera from BNT162b2 or Coronavac Vaccine Recipients. Clinical Infectious Diseases. [Google Scholar] [CrossRef] 
[57] Dejnirattisai, W., Shaw, R.H., Supasa, P., et al. (2022) Reduced Neutralisation of SARS-CoV-2 Omicron, B.1.1.529 Variant by Post-Immunisation Serum. Lancet, 399, 234-236. [Google Scholar] [CrossRef] 
[58] Kannan, S.R., Spratt, A.N., Sharma, K., et al. (2022) Omicron SARS-CoV-2 Variant: Unique Features and Their Impact on Pre-Existing Antibodies. Journal of Autoimmunity, 126, Article ID: 102779. [Google Scholar] [CrossRef] [PubMed]
[59] Hu, J., Peng, P., Cao, X., et al. (2022) Increased Immune Escape of the New SARS-CoV-2 Variant of Concern Omicron. Cellular & Molecular Immunology, 19, 293-295. [Google Scholar] [CrossRef] [PubMed]
[60] Wang, S.F., Tseng, S.P., Yen, C.H., et al. (2014) Antibody-Dependent SARS Coronavirus Infection Is Mediated by Antibodies against Spike Proteins. Biochemical and Biophysical Research Communications, 451, 208-214. [Google Scholar] [CrossRef] [PubMed]
[61] Smatti, M.K., Al Thani, A.A., Yassine, H.M. (2018) Viral-Induced Enhanced Disease Illness. Frontiers in Microbiology, 9, Article No. 2991. [Google Scholar] [CrossRef] [PubMed]
[62] Liu, Y., Soh, W.T., Kishikawa, J.I., et al. (2021) An Infectivity-Enhancing Site on the SARS-CoV-2 Spike Protein Targeted by Antibodies. Cell, 184, 3452-3466.E18. [Google Scholar] [CrossRef] [PubMed]
[63] Simon-Loriere, E. and Schwartz, O. (2022) Towards SARS-CoV-2 Serotypes? Nature Reviews Microbiology, 20, 187-188. [Google Scholar] [CrossRef] [PubMed]
[64] Liu, L., Iketani, S., Guo, Y., et al. (2022) Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. Nature, 602, 676-681. [Google Scholar] [CrossRef] [PubMed]
[65] Guigon, A., Faure, E., Lemaire, C., et al. (2022) Emergence of Q493R Mutation in SARS-CoV-2 Spike Protein during Bamlanivimab/Etesevimab Treatment and Resistance to Viral Clearance. Journal of Infection, 84, 248-288. [Google Scholar] [CrossRef] [PubMed]
[66] Geurtsvan Kessel, C.H., Geers, D., Schmitz, K.S., et al. (2022) Divergent SARS CoV-2 Omicron-Reactive T- and B Cell Responses in COVID-19 Vaccine Recipients. Science Immunology, 7, eabo2202. [Google Scholar] [CrossRef] [PubMed]
[67] Bertoletti, A., Le Bert, N., Qui, M., et al. (2021) SARS-CoV-2-Specific T Cells in Infection and Vaccination. Cellular & Molecular Immunology, 18, 2307-2312. [Google Scholar] [CrossRef] [PubMed]
[68] Choi, S.J., Kim, D.U., Noh, J.Y., et al. (2022) T Cell Epitopes in SARS-CoV-2 Proteins Are Substantially Conserved in the Omicron Variant. Cellular & Molecular Immunology, 19, 447-448. [Google Scholar] [CrossRef] [PubMed]
[69] Grifoni, A., Sidney, J., Vita, R., et al. (2021) SARS-CoV-2 Human T Cell Epitopes: Adaptive Immune Response against COVID-19. Cell Host & Microbe, 29, 1076-1092. [Google Scholar] [CrossRef] [PubMed]
[70] Gao, Y., Cai, C., Grifoni, A., et al. (2022) Ancestral SARS-CoV-2-Specific T Cells Cross-Recognize the Omicron Variant. Nature Medicine, 28, 472-476. [Google Scholar] [CrossRef] 
[71] Sherina, N., Piralla, A., Du, L., et al. (2021) Persistence of SARS-CoV-2-Specific B and T Cell Responses in Convalescent COVID-19 Patients 6-8 Months after the Infection. Med, 2, 281-295.e4. [Google Scholar] [CrossRef] [PubMed]
[72] Fantini, J., Yahi, N., Colson, P., et al. (2022) The Puzzling Mutational Landscape of the SARS-2-Variant Omicron. Journal of Medical Virology, 94, 2019-2025. [Google Scholar] [CrossRef] [PubMed]
[73] Motozono, C., Toyoda, M., Zahradnik, J., et al. (2021) SARS-CoV-2 Spike L452R Variant Evades Cellular Immunity and Increases Infectivity. Cell Host & Microbe, 29, 1124-1136.e11. [Google Scholar] [CrossRef] [PubMed]
[74] Mok, C.K.P., Cheng, S.M.S., Chen, C., et al. (2022) A RCT Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac. American Journal of Respiratory and Critical Care Medicine, 205, 844-847. [Google Scholar] [CrossRef] [PubMed]
[75] Costa Clemens, S.A., Weckx, L., Clemens, R., et al. (2022) Heterologous versus Homologous COVID-19 Booster Vaccination in Previous Recipients of Two Doses of CoronaVac COVID-19 Vaccine in Brazil (RHH-001): A Phase 4, Non-Inferiority, Single Blind, Randomised Study. Lancet, 399, 521-529. [Google Scholar] [CrossRef] 
[76] Cao, Y., Hao, X., Wang, X., et al. (2022) Humoral Immunogenicity and Reactogenicity of CoronaVac or ZF2001 Booster after Two Doses of Inactivated Vaccine. Cell Research, 32, 107-109. [Google Scholar] [CrossRef] [PubMed]
[77] 王康泓, 丁崇正. SARS-CoV-2抗原表位分析及相关疫苗研发的进展与挑战[J]. 微生物学通报, 2021, 48(1): 241-252.
[78] Krause, P.R., Fleming, T.R., Peto, R., et al. (2021) Considerations in Boosting COVID-19 Vaccine Immune Responses. Lancet, 398, 1377-1380. [Google Scholar] [CrossRef] 
[79] 岳小林, 王雅葳, 王欣. 新型冠状病毒肺炎mRNA疫苗相关淋巴结病的研究现状[J]. 药物不良反应杂志, 2021, 23(11): 592-596.
[80] Wolter, N., Jassat, W., Walaza, S., et al. (2022) Early Assessment of the Clinical Severity of the SARS-CoV-2 Omicron Variant in South Africa: A Data Linkage Study. Lancet, 399, 437-446. [Google Scholar] [CrossRef] 
[81] Abdullah, F., Myers, J., Basu, D., et al. (2022) Decreased Severity of Disease during the First Global Omicron Variant Covid-19 Outbreak in a Large Hospital in Tshwane, South Africa. International Journal of Infectious Diseases, 116, 38-42. [Google Scholar] [CrossRef] [PubMed]
[82] Modes, M.E., Directo, M.P., Melgar, M., et al. (2022) Clinical Characteristics and Outcomes among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of, B.1.617.2 (Delta) and, B.1.1.529 (Omicron) Variant Predominance—One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. Morbidity and Mortality Weekly Report, 71, 217-223. [Google Scholar] [CrossRef] [PubMed]
[83] Espenhain, L., Funk, T., Overvad, M., et al. (2021) Epidemiological Characterisation of the First 785 SARS-CoV-2 Omicron Variant Cases in Denmark, December 2021. Euro Surveill, 26, Article ID: 2101146. [Google Scholar] [CrossRef] 
[84] Brandal, L.T., MacDonald, E., Veneti, L., et al. (2021) Outbreak Caused by the SARS-CoV-2 Omicron Variant in Norway, November to December 2021. Euro Surveill, 26, Article ID: 2101147. [Google Scholar] [CrossRef] 
[85] Kim, M.K., Lee, B., Choi, Y.Y., et al. (2022) Clinical Characteristics of 40 Patients Infected with the SARS-CoV-2 Omicron Variant in Korea. Journal of Korean Medical Science, 37, e31. [Google Scholar] [CrossRef] [PubMed]
[86] Lopez, L., Sang, P.C., Tian, Y., et al. (2020) Dysregulated Interferon Response Underlying Severe COVID-19. Viruses, 12, 1433. [Google Scholar] [CrossRef] [PubMed]
[87] Chen, J. and Wei, G.W. (2022) Omicron, B.A.2 (B.1.1.529.2): High Potential to Becoming the Next Dominating Variant. Preprint. ArXiv, arXiv:2202.05031v1. [Google Scholar] [CrossRef] [PubMed]
[88] Desingu, P.A. and Nagarajan, K. (2022) Omicron, BA.2 Lineage Spreads in Clusters and Is Concentrated in Denmark. Journal of Medical Virology, 94, 2360-2364. [Google Scholar] [CrossRef] [PubMed]
[89] 孙丹, 杨金燕, 夏婷婷, 等. 新型冠状病毒Omicron变异株的流行病学特征及防控研究进展[J/OL]. 中华医院感染学杂志: 1-5.
https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CAPJ&dbname=CAPJLAST&filename=ZHYY2022050500W&uniplatform=NZKPT&v=yXnxOaaFz0JYxfn59cmAFggCl7dOYH5WuTcuLg4xRhd0n-XgLDq0ghztaFoQ1neC, 2022-02-11.
[90] Ahmed, W., Bivins, A., Smith, W.J.M., et al. (2022) Detection of the Omicron (B.1.1.529) Variant of SARS-CoV-2 in Aircraft Wastewater. Science of the Total Environment, 820, Article ID: 153171. [Google Scholar] [CrossRef] [PubMed]
[91] Kirby, A.E., Welsh, R.M., Marsh, Z.A., et al. (2022) Notes from the Field: Early Evidence of the SARS-CoV-2 B.1.1.529 (Omicron) Variant in Community Wastewater—United States, November-December 2021. Morbidity and Mortality Weekly Report, 71, 103-105. [Google Scholar] [CrossRef] [PubMed]

为你推荐